The National Institute for Health and Care Excellence (NICE) has recommended Janssen's Tremfya as a cost-effective treatment for plaque psoriasis, Pharma Times reported on Friday.
A Final Appraisal Determination was published by the cost regulator to back the funding for the drug, which was launched in the UK in the November.
Tremfya (guselkumab) is the first biologic to selectively target interleukin (IL)-23, a key protein involved in the immune inflammatory response in psoriasis.
The Final Appraisal Determination was fast-tracked as a result of the European approval in November last year. Approval was based on Phase III trials, VOYAGE 1 and VOYAGE 2, which showed high rates of skin clearance.
Janssen has agreed a confidential patient access scheme with the Department of Health and Social Care, offering the drug to the NHS at a reduced cost.
Galderma receives FDA Complete Response Letter for RelabotulinumtoxinA US filing
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
genedrive partners with Thermo Fisher Scientific to develop high-throughput CYP2C19 test
Anivive Lifesciences' Laverdia receives FDA approval to treat canine lymphoma
Lupin's Enzalutamide Tablets receive for tentative US FDA approval
bioMérieux files FDA application for rapid vaginitis diagnostic panel
Ionis licenses ex-US rights to zilganersen for Alexander disease to Recordati
Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US
CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
ZETA SURGICAL reports first patient treated with Zeta TMS Navigation System at HOPE Therapeutics